1. Begum NJ, Glatting G, Wester H-J, Eiber M, Beer AJ, Kletting P. The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model. Sci Rep 2019; 9: 20041.
  2. Damjanovic J, Janssen JC, Prasad V, Diederichs G, Walter T, Brenner W, Makowski MR. Ga-68-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer. Cancer Imaging 2019; 19: 9.
  3. Diehl-Schmid J, Licata A, Goldhardt O, Forstl H, Yakushew I, Otto M, Anderl-Straub S, Beer A, Ludolph AC, Landwehrmeyer GB, Levin J, Danek A, Fliessbach K, Spottke A, Fassbender K, Lyros E, Prudlo J, Krause BJ, Volk A, Edbauer D, Schroeter ML, Drzezga A, Kornhuber J, Lauer M, Grimmer T. FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Transl Psychiatry 2019; 9: 54.
  4. Eberhardt N, Kneer K, Prasad V. Die Wichtigkeit des „Machine Learning“ und der Texturanalyse in der Onkologie anhand der Fusionsbildgebung. Der Nuklearmediziner 2019; 42(02): 133-143. doi: 10.1055/a-0943-0020.
  5. Engler A, Shi R, Beer M, Schmidberger J, Kratzer W, Barth TFE, Grimm J, Hillenbrand A, Henne-Bruns D, Gruener B, Beer AJ, Graeter T, Barth TF, Baumann S, Bloehdorn J, Klein K, Schlingeloff P, Theis F, Echinococcosis Working G. Simple liver cysts and cystoid lesions in hepatic alveolar echinococcosis: a retrospective cohort study with Hounsfield analysis. Parasite 2019; 26: 9.
  6. Felder S, Jann H, Arsenic R, Denecke T, Prasad V, Knappe-Drzikova B, Maasberg S, Wiedenmann B, Pavel M, Pascher A, Pape UF. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocr Relat Cancer 2019; 26: 751-63.
  7. Gomarteli K, Fleckenstein J, Kirschner S, Bobu V, Brockmann MA, Henzler T, Meyer M, Riffel P, Schonberg SO, Veldwijk MR, Kranzlin B, Hoerner C, Glatting G, Wenz F, Herskind C, Giordano FA. Radiation-induced malignancies after intensity-modulated versus conventional mediastinal radiotherapy in a small animal model. Sci Rep 2019; 9: 10.
  8. Hechler V, Rink M, Beyersdorff D, Beer M, Beer AJ, Panebianco V, Pecoraro M, Bolenz C, Salomon G. [The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics-status quo]. Urologe A 2019; 58: 1443-50.
  9. Hillenbrand A, Lemke J, Henne-Bruns D, Beer AJ, Prasad V. Can Met-PET/CT Predict Sporadic Multiglandular Hyperparathyroidism? Report of a Case and Review of the Literature. Case Rep Endocrinol 2019; 2019: 1791740.
  10. Huang K, Brenner W, Prasad V. Tumor Lysis Syndrome: A Rare but Serious Complication of Radioligand Therapies. J Nucl Med 2019; 60: 752-5.
  11. Jiménez-Franco LD, Kletting P, Glatting G. Möglichkeiten zur Verbesserung der Dosimetrie und Therapieplanung in der Molekularen Radiotherapie durch maschinelles Lernen. Der Nuklearmediziner 2019; 42: 148-56.
  12. Kewitz-Hempel S, Kurch L, Cepelova M, Volkmer I, Sauerbrey A, Conrad E, Knirsch S, Popperl G, Steinbach D, Beer AJ, Kramm CM, Sahlmann CO, Erdlenbruch B, Reinbold WD, Odparlik A, Sabri O, Kluge R, Staege MS. Impact of rs12917 MGMT Polymorphism on F-18 FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL). Mol Imaging Biol 2019; 21: 1182-91.
  13. Kletting P, Thieme A, Eberhardt N, Rinscheid A, D'Alessandria C, Allmann J, Wester HJ, Tauber R, Beer AJ, Glatting G, Eiber M. Modeling and Predicting Tumor Response in Radioligand Therapy. J Nucl Med 2019; 60: 65-70.
  14. Kretz D, Hesser J, Glatting G, Diehl S, Wenz F, He W, Zheng L. Modeling sphere dynamics in blood vessels for SIRT pre-planning - To fathom the potential and limitations. Z Med Phys 2019; 29: 5-15.
  15. Meissner S, Janssen JC, Prasad V, Diederichs G, Hamm B, Brenner W, Makowski MR. Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: Comparison to (68)Ga-PSMA PET-CT. Sci Rep 2019; 9: 10727.
  16. Pala A, Reske SN, Eberhardt N, Scheuerle A, Konig R, Schmitz B, Beer AJ, Wirtz CR, Coburger J. Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and C-11-methionine positron emission tomography in resection of glioblastoma: a prospective study. Neurosurg Rev 2019; 42: 471-9.
  17. Peschmann AL, Beer M, Ammann B, Dreyhaupt J, Kneer K, Beer AJ, Beltinger C, Steinbach D, Cario H, Neubauer H. Quantitative DWI predicts event-free survival in children with neuroblastic tumours: preliminary findings from a retrospective cohort study. Eur Radiol Exp 2019; 3: 6.
  18. Prasad V. Künstliche Intelligenz in der Bildgebung. Nuklearmediziner 2019; 42: 95-6.
  19. Prasad V, Modlin I, Chiti A. Why wait for posterity (or the future) to provide proof to savor the elixir of precision oncology? Read interviews with intellects and dine with the doyens of discovery. Eur J Nucl Med Mol Imaging 2019; 46: 2418-20.
  20. Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu-PSMA therapy. Med Phys 2019; 46: 5861-6.
  21. Rinscheid A, Lee J, Kletting P, Beer AJ, Glatting G. A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy. Z Med Phys 2019; 29: 314-25.
  22. Werner T, Berthold J, Hueso-Gonzalez F, Koegler T, Petzoldt J, Roemer K, Richter C, Rinscheid A, Straessner A, Enghardt W, Pausch G. Processing of prompt gamma-ray timing data for proton range measurements at a clinical beam delivery. Phys Med Biol 2019; 64: 105023.
  23. Winter G, Vogt A, Jimenez-Franco LD, Rinscheid A, Yousefzadeh-Nowshahr E, Solbach C, Beer AJ, Glatting G, Kletting P. Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands. Nucl Med Biol 2019; 72-73: 20-5.